Tech Company Financing Transactions

Zalicus Funding Round

Zalicus, based in Cambridge, scored $30 million from Boston Millennia Partners, Canaan Partners and Easton Capital.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series C
Proceeds Purpose
The funds from this financing will be used to progress multiple programs from the CombinatoRx pipeline through the clinic.

Company Information

Company Status
Acquired or Merged
Mailing Address
245 First St. 3rd Floor
Cambridge, MA 02142
Email Address
Our pipeline includes Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and Synavive, in Phase 2 development for rheumatoid arthritis.
Zalicus LinkedIn Company Profile
Social Media
Zalicus Company Twitter Account
Company News
Zalicus News
Zalicus on Facebook
Zalicus on YouTube

Management Team

Email & Social
Chief Executive Officer
Mark Corrigan
  Mark Corrigan LinkedIn Profile  Mark Corrigan Twitter Account  Mark Corrigan News  Mark Corrigan on Facebook
Chief Financial Officer
Justin Renz
  Justin Renz LinkedIn Profile  Justin Renz Twitter Account  Justin Renz News  Justin Renz on Facebook



Browse more venture capital transactions:

Prev: 3/10/2004: Phylogix venture capital transaction
Next: 3/11/2004: BioRexis Pharmaceutical venture capital transaction


Share this article


Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary